title: Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab.
abstract: Anti-programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab are becoming increasingly important in the treatment of melanoma and non-small cell lung cancer. These agents are known to induce many immune-related adverse events, but rapid-onset nephritis and immune-related hyponatremia have not been described to date. We describe the case of an adult patient who developed severe hyponatremia and rapid-onset nephritis following the first infusion of nivolumab for metastatic melanoma.
authors.affiliation: University of Wyoming School of Pharmacy, Health Sciences Center, Room 292, 1000 E. University Ave., Dept. 3375, Laramie, WY, 82071, USA. jvandive@uwyo.edu.|Swedish Family Medicine Residency Program, Littleton, CO, USA. jvandive@uwyo.edu.
authors.forename: Jeremy W
authors.initials: JW
authors.lastname: Vandiver
authors.affiliation: Swedish Family Medicine Residency Program, Littleton, CO, USA.
authors.forename: Zachary
authors.initials: Z
authors.lastname: Singer
authors.affiliation: University of Wyoming School of Pharmacy, Health Sciences Center, Room 292, 1000 E. University Ave., Dept. 3375, Laramie, WY, 82071, USA.
authors.forename: Cara
authors.initials: C
authors.lastname: Harshberger
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced* / Q000209:etiology; D008875:Middle Aged; D009393:Nephritis / Q000139:chemically induced* / Q000209:etiology; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000077594:Nivolumab